Navigation Links
CVS Caremark Research Finds New, More Accurate Method for Classifying Patient Medication Adherence Behaviors

WOONSOCKET, R.I., Sept. 12, 2013 /PRNewswire/ -- Researchers at CVS Caremark (NYSE: CVS) and Brigham and Women's Hospital have found that a new approach to classifying patients by their long-term medication adherence behavior may be more accurate than traditional approaches. In a study published in the September 2013 issue of Medical Care, the researchers followed more than 264,000 statin-users over a 15-month period and created measures to account for different adherence behaviors. The researchers identified key groups into which various patients would fall based on these measures in an effort to predict and compare their long-term adherence patterns.

(Logo: )

The study utilized a new method of categorizing adherence called group-based trajectory modeling, which is based upon observed patterns of medication-filling over time.  This method allows researchers to more accurately capture and describe adherence compared to techniques that simply classify patients as adherent or not, using average levels of adherence.  In addition, the trajectory patterns that are created should allow for more targeted interventions to address non-adherence.  In this study, use of trajectory modeling was especially useful for accounting for variable patterns of intermittent and long-term adherence behaviors.

"Our findings could help facilitate research on medication adherence and medication effectiveness in a variety of ways," said Niteesh Choudhry, MD, PhD, associate physician, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and associate professor, Harvard Medical School. "For example, by using group-based trajectory modeling, we could help identify patients with distinct patterns of adherence so that health care professionals could appropriately target interventions.  In addition, data related to the quantity and timing of medication availability could help improve our understanding of the effects of nonadherence on clinical outcomes."

Based on the study group, researchers categorized patients into six distinct groups according to characteristics:

  • Nearly always adherent (23.4 percent)
  • Brief gap in medication use or filled irregularly during the first nine months, but improved during the last six months (11.4 percent)
  • Slowly declining adherence throughout the 15 month period (11.3 percent)
  • Used statins only occasionally across the 15 month study period (15.0 percent)
  • Rapid decline in statin use after initiation (19.3 percent)
  • Virtually no fills after their initial fill (23.4 percent)

Group trajectory modeling also identified certain characteristics that impact medication adherence.  For example, among the study participants, on average, those patients with the best adherence were older, more likely to have a higher income, more likely to be a high school graduate and less likely to be black. In addition, those with the best adherence were more likely to be a Medicare Part D beneficiary or live in New England. Those with the lowest adherence rates tended to be generally younger, male and less likely to have an initial prescription that provided them with more than a 30-day supply of medication.

"CVS Caremark continues to engage in cutting-edge research using novel approaches to analyze data so we can better understand the adherence behaviors and needs of the patients we support," said Troyen A. Brennan, MD, MPH, executive vice president and chief medical officer of CVS Caremark.  "The use of trajectory models could help us more accurately identify patients at risk for medication nonadherence, so we can develop and implement targeted interventions to help them stay on their medications for chronic health conditions."

CVS Caremark is focused on developing programs to help improve medication adherence.  The study described here helps improve the industry's overall understanding of medication adherence and enables CVS Caremark to develop more targeted programs to address the underlying behaviors that contribute to nonadherence. CVS Caremark plans to use these research results along with other key information learned to identify, develop and pilot breakthrough interventions that will help improve medication adherence for the patients we support. The company is currently evaluating and piloting a number of interventions that range from the development of models to predict a patient's adherence behaviors in order to better target interventions; to the use of medication reminder devices to help combat forgetfulness; to digital interventions that engage patients to encourage adherence.

CVS Caremark has been working in a multi-year collaboration with Brigham and Women's Hospital to research pharmacy claims data in order to better understand patient behavior, particularly around medication adherence. Annual excess health care costs due to medication non-adherence in the U.S. have been estimated to be as much as $290 billion.

About CVS Caremark
CVS Caremark is dedicated to helping people on their path to better health as the largest integrated pharmacy company in the United States. Through the company's more than 7,500 CVS/pharmacy stores; its leading pharmacy benefit manager serving more than 60 million plan members; and its retail health clinic system, the largest in the nation with more than 600 MinuteClinic locations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare Part D Prescription Drug Plans. As a pharmacy innovation company with an unmatched breadth of capabilities, CVS Caremark continually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisor program that helps people with chronic diseases such as diabetes obtain and stay on their medications. Find more information about how CVS Caremark is reinventing pharmacy for better health at

Media Contacts:
Christine Cramer
CVS Caremark
(401) 770 3317

SOURCE CVS Caremark Pharmacy Services
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Uses Data to Combat National Prescription Drug Abuse Epidemic; Program Details Published in New England Journal of Medicine Online
2. CVS Caremark Hosts Grand Opening of State-of-the-Art Mail Service Pharmacy and Customer Center
3. CVS Caremarks Accordant Health Services Launches New Member-Focused Web Site
4. CVS Caremark Reports Record Second Quarter Results
5. CVS Caremark Announces Agreement in Principle with the Securities and Exchange Commission
6. CVS Caremark Corporation To Hold Second Quarter 2013 Conference Call
7. CVS Caremark in Partnership with Ocean Conservancy Cleans Up Nearly 25,000 Pounds of Trash from Shorelines across the Country
8. CVS Caremark Corporation Announces Quarterly Dividend
9. CVS Caremark To Present At William Blair & Companys 33rd Annual Growth Stock Conference
10. CVS Caremark Donates Over $750,000 to The One Fund Boston
11. CVS Caremark Reports Strong First Quarter Results
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):